Personalised ASV therapy has never been easier
This product may not be available in all countries.
The AutoSet CS-A with PaceWave is ResMed’s most responsive ASV technology to stabilise the ventilation of patients with central sleep apnea (CSA), mixed sleep apnea and periodic breathing, with or without obstructive sleep apnea.
Clinically studied, ResMed's pioneering PaceWave technology is the only ASV therapy to target the patient’s own recent minute ventilation (MV). PaceWave monitors the entire breath with split-second resolution to learn and predict a patient’s unique breathing pattern, rapidly responding to changes and steadily keeping your patient on target throughout the night.
PaceWave rapidly stabilises breathing and blood gases helping improve sleep quality.1,2
Additionally, the AutoSet CS-A features the new ASVAuto mode with an automatically adjusting EPAP to automatically maintain an open upper airway.
It also provides greater peace of mind with four alarms to monitor your sensitive patients.
The comfort features of the S9 platform in combination with PaceWave’s ability to provide synchrony over a wider range of breath rates and personalised breathing, provides a new level of comfort supporting patient compliance.
Modes: CPAP, ASV and ASVAuto
Alarms: High leak, Non-Vented Mask, Low Minute Ventilation, Low SpO2
- Climate Control, with the H5i heated humidifier and ClimateLineMAX tube, maintains ideal humidification according to real-time environment.
- Easy-Breathe motor offers the quietest therapy available.
- Easy-to-use controls and color LCD make menu navigation simple and intuitive.
- SlimLine and ClimateLine tubes are exceptionally slim and lightweight, virtually eliminating tube drag.
How to buy
After receiving your official diagnosis, you can get your mask and device from your local ResMed accredited outlet. Find your nearest outlet here.
Morgenthaler TI, Gay PC, Gordon N, Brown LK. Adaptive servoventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes. Sleep. 2007;30(4):468-475.
ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea.